ClinicalTrials.gg
CompletedNCT01716208Updated May 11, 2021Results posted

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

A Phase 2 interventional study of Ofatumumab + Fresh Frozen Plasma in Chronic Lymphocytic Leukemia, sponsored by Joseph Tuscano. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Joseph Tuscano · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing ofatumumab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ofatumumab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
26th of 33
12 · median 33
Started
2013
with 2 others
Phase 2
26 of 33
none open now
Registered
29th of 33
by date

Among the 33 studies testing ofatumumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 26th largest by enrollment, is one of 3 that started in 2013, is one of 26 in phase 2, and was the 29th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 33 studies testing ofatumumab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ofatumumab

ofatumumab: first FDA approval 2009 (KESIMPTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing ofatumumab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

It has been shown that many patients with lymphoma or chronic lymphocytic leukemia (CLL)have low levels of complement. Several drugs have been approved by the Food and Drug Administration (FDA) for use in this cancer. However, these drugs are often used as combination therapies which means two or more drugs are part of the treatment. Many people, especially elderly patients, cannot put up with the use of multiple drugs because of the side effects.

The main purpose of this study is to see if patients respond to therapy with human plasma (known as fresh frozen plasma or FFP) and ofatumumab. Another purpose of the study is to find out if this therapy will increase chances of getting rid of leukemia. This study will also look at the levels of complement in your blood. The levels of complement may allow better understanding of whether increasing the levels of complement by giving FFP may help control leukemia.

Read the detailed description

The vast majority of patients with CLL are elderly and often they cannot tolerate standard multi-agent chemotherapeutic or biochemotherapeutic approaches. Based on this, less toxic and more effective treatment options are needed.

Ofatumumab has proven to be effective in patients with relapsed and/or refractory CLL. Previous studies have shown that ofatumumab is more effective than rituximab at activating complement and utilizing complement-dependent cytotoxicity (CDC).

This study will investigate treating relapsed/refractory CLL patients with FFP in combination with ofatumumab. The hypothesis is that patients with CLL have low complement levels and when they get treated with humanized antibodies like rituximab or ofatumumab these levels drop even further. Both these antibodies utilize complement to exert their cytotoxic effect, thus we hypothesize that by replacing complement levels with FFP we can enhance the efficacy of ofatumumab.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Fresh Frozen Plasma
  • Complement
  • Monoclonal Antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a pathological diagnosis of B-cell CLL.
  • Patients must have received prior rituximab therapy and must have recovered from all non-hematologic toxicities. (Previous radiation is allowed as long as patients have recovered from all treatment related toxicities).
  • Patients must meet the following laboratory values:

    • > 9.0 g/dl
    • > 50,000/mm3
    • Creatinine \< 2.0 times the institutional
    • /SGPT \< 2.5 times the institutional upper limit of normal
    • Total \<1. 5 times the institutional upper limit of normal
    • Alkaline phosphatase \<2.5 times upper limit of normal (unless due to disease involvement of the liver or bone marrow)
  • Patients must be at least 18 years of age.
  • Patients must have a performance status of 0-2 by criteria.
  • All patients must be informed of the nature of this study and must sign and give written consent in accordance with institutional and federal guidelines.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have current active hepatic or biliary disease.
  • Having received rituximab or rituximab-containing therapy within the prior 3 months.
  • Treatment with any known therapeutic or experimental therapy within 4 weeks prior to enrollment, or currently participating in any other interventional clinical study.
  • Other past or current .
  • Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy.
  • Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active .
  • History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae.
  • Known positive.
  • cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure, and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
  • Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.
  • Positive serology for (HB) defined as a positive test for HBsAg.
  • Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result.
  • Pregnant or lactating women.
  • Women of , including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate from study start to one year after the last dose of protocol therapy.
  • Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
  • Receiving warfarin.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ofatumumab + Fresh Frozen Plasma

    Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).

    Drug: Ofatumumab + Fresh Frozen Plasma

Interventions

06

What researchers measure

Primary outcomes

  1. Response to Therapy

    Defined as complete, or partial response, and progression-free survival. Measured by National Cancer Institute - Working Group and International Workshop on Chronic Lymphocytic Leukemia

    Time frame: Up to 37 months.

Secondary outcomes

  1. Number of Participants With Toxicities

    Toxicities will be graded according to the NCI CTCAE v4.0.

    Time frame: Up to two years

  2. Overall Survival

    Count of participants known to be alive up to two years from the time from start of treatment.

    Time frame: Up to two years

  3. Percent Reduction in Complement Levels (CH50)

    Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity.

    Time frame: Up to two weeks

07

Results

Posted May 11, 2021

Participant flow

Participant flow — Overall Study
MilestoneOfatumumab + Fresh Frozen Plasma
Started12
Completed12
Not completed0

Outcome measures

PrimaryResponse to Therapy

Defined as complete, or partial response, and progression-free survival. Measured by National Cancer Institute - Working Group and International Workshop on Chronic Lymphocytic Leukemia

Time frame:
Up to 37 months.
Reported as:
Count of participants · Participants
Response to Therapy
ParticipantsOfatumumab + Fresh Frozen Plasma
PR10
CR2
SecondaryNumber of Participants With Toxicities

Toxicities will be graded according to the NCI CTCAE v4.0.

Time frame:
Up to two years
Reported as:
Count of participants · Participants
Number of Participants With Toxicities
ParticipantsOfatumumab + Fresh Frozen Plasma
Blood bilirubin increased1
Chills1
Constipation1
Cough1
Creatinine increased2
Dehydration1
Dizziness2
Dyspepsia1
Dyspnea3
Blepharitis1
Fatigue5
Flushing1
Gastroesophageal reflux disease1
Feverish1
Generalized muscle weakness1
Headache4
Hiccups1
Hyperkalemia1
Hypertension2
Hypocalcemia1
hyponatremia1
Infusion related reaction7
Insomnia2
Lung infection1
Lymph node pain1
Lymphocyte count increased2
Nausea5
Neutrophil count decreased4
Palpitations1
Paresthesia1
peripheral sensory neuropathy1
Platelet count decreased4
Rash acneiform1
Rash maculo-papular1
Aspergillus Pneumonia1
Sinus tachycardia1
Sinusitis2
Rash1
Lesions on face, neck, scalp1
Guttate Psoriasis (Exacerbation of Symptoms)1
Skin infection, Eyelid4
Upper respiratory infection1
Wheezing1
White blood cell decreased3
SecondaryOverall Survival

Count of participants known to be alive up to two years from the time from start of treatment.

Time frame:
Up to two years
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsOfatumumab + Fresh Frozen Plasma
Overall Survival11
SecondaryPercent Reduction in Complement Levels (CH50)

Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity.

Time frame:
Up to two weeks
Reported as:
Mean · Percentage change
Percent Reduction in Complement Levels (CH50)
Percentage changeOfatumumab + Fresh Frozen Plasma
Percent Reduction in Complement Levels (CH50)54 (20 to 100)

Adverse events

Collected over Up to 2 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ofatumumab + Fresh Frozen Plasma1/12 (8.3%)2/12 (16.7%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
EventOfatumumab + Fresh Frozen Plasma
Lung infectionInfections and infestations1/12
Atrial fibrillationCardiac disorders1/12
Most frequent other events
Showing 10 of 46
Most frequent other events
EventOfatumumab + Fresh Frozen Plasma
Infusion related reactionInjury, poisoning and procedural complications7/12
AnemiaBlood and lymphatic system disorders6/12
FatigueGeneral disorders5/12
NauseaGastrointestinal disorders5/12
Allergic reactionImmune system disorders4/12
HeadacheNervous system disorders4/12
Neutrophil count decreasedInvestigations4/12
Platelet count decreasedInvestigations4/12
Skin infectionInfections and infestations4/12
AnorexiaMetabolism and nutrition disorders3/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ofatumumab + Fresh Frozen Plasma
<=18 years0
Between 18 and 65 years7
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Ofatumumab + Fresh Frozen Plasma
Female2
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ofatumumab + Fresh Frozen Plasma
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Ofatumumab + Fresh Frozen Plasma
United States12
08

Study locations

1 site
  • University of California Comprehensive Cancer Center
    Sacramento, California 95817, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Oct 2019, 80 months.

Results were first posted in May 2021, 1 year 7 months after primary completion.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's 80 months is close to that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2012
First posted
Oct 29, 2012
StartActual
Jan 14, 2013
Primary completionActual
Oct 1, 2019
CompletionActual
Oct 1, 2020
Results first posted
May 11, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01716208
Lead sponsor
Joseph Tuscano
Collaborators
GlaxoSmithKline
Responsible party
Joseph Tuscano (Principal Investigator, University of California, Davis) — Sponsor-investigator
First posted
Oct 29, 2012
Start date
Jan 14, 2013
Primary completion
Oct 1, 2019
Completion
Oct 1, 2020
Results posted
May 11, 2021
Last update
May 11, 2021

Study contacts

Joseph Tuscano, MD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ofatumumab · Human plasma

Start the discussion